Similarly, we observed a higher frequency of CCNE1 amplification in gastric adenocarcinoma metastatic sites (6.0%) such as liver and lymph node metastases (11.1% and 10.4%, respectively) compared with primary tumors (3.9%; P = 0.037, Fisher exact test). Here, CCNE1 is linked to gastric adenocarcinoma.